vs
HALOZYME THERAPEUTICS, INC.（HALO）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $-139.5M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs -100.0%）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
HALO vs RVMD — 直观对比
营收规模更大
HALO
是对方的Infinity倍
$0
自由现金流更多
HALO
多$357.1M
$-139.5M
两年增速更快
HALO
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $451.8M | $0 |
| 净利润 | $-141.6M | $-194.6M |
| 毛利率 | 82.6% | — |
| 营业利润率 | -20.6% | — |
| 净利率 | -31.3% | — |
| 营收同比 | 51.6% | — |
| 净利润同比 | -203.3% | -20.4% |
| 每股收益（稀释后） | $-1.13 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HALORVMD
| Q4 25 | $451.8M | — | ||
| Q3 25 | $354.3M | — | ||
| Q2 25 | $325.7M | — | ||
| Q1 25 | $264.9M | — | ||
| Q4 24 | $298.0M | $0 | ||
| Q3 24 | $290.1M | $0 | ||
| Q2 24 | $231.4M | $0 | ||
| Q1 24 | $195.9M | $0 |
净利润HALORVMD
| Q4 25 | $-141.6M | — | ||
| Q3 25 | $175.2M | — | ||
| Q2 25 | $165.2M | — | ||
| Q1 25 | $118.1M | — | ||
| Q4 24 | $137.0M | $-194.6M | ||
| Q3 24 | $137.0M | $-156.3M | ||
| Q2 24 | $93.2M | $-133.2M | ||
| Q1 24 | $76.8M | $-116.0M |
毛利率HALORVMD
| Q4 25 | 82.6% | — | ||
| Q3 25 | 84.4% | — | ||
| Q2 25 | 85.8% | — | ||
| Q1 25 | 81.7% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 82.9% | — | ||
| Q1 24 | 85.5% | — |
营业利润率HALORVMD
| Q4 25 | -20.6% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.2% | — | ||
| Q1 25 | 53.4% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 50.7% | — | ||
| Q1 24 | 48.8% | — |
净利率HALORVMD
| Q4 25 | -31.3% | — | ||
| Q3 25 | 49.5% | — | ||
| Q2 25 | 50.7% | — | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | 46.0% | — | ||
| Q3 24 | 47.2% | — | ||
| Q2 24 | 40.3% | — | ||
| Q1 24 | 39.2% | — |
每股收益（稀释后）HALORVMD
| Q4 25 | $-1.13 | — | ||
| Q3 25 | $1.43 | — | ||
| Q2 25 | $1.33 | — | ||
| Q1 25 | $0.93 | — | ||
| Q4 24 | $1.06 | $-1.13 | ||
| Q3 24 | $1.05 | $-0.94 | ||
| Q2 24 | $0.72 | $-0.81 | ||
| Q1 24 | $0.60 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.8M | $2.3B |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $48.8M | $2.3B |
| 总资产 | $2.5B | $2.6B |
| 负债/权益比越低杠杆越低 | 43.89× | — |
8季度趋势，按日历期对齐
现金及短期投资HALORVMD
| Q4 25 | $133.8M | — | ||
| Q3 25 | $419.7M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $176.3M | — | ||
| Q4 24 | $115.8M | $2.3B | ||
| Q3 24 | $154.3M | $1.5B | ||
| Q2 24 | $187.9M | $1.6B | ||
| Q1 24 | $164.6M | $1.7B |
总债务HALORVMD
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益HALORVMD
| Q4 25 | $48.8M | — | ||
| Q3 25 | $503.9M | — | ||
| Q2 25 | $332.7M | — | ||
| Q1 25 | $482.3M | — | ||
| Q4 24 | $363.8M | $2.3B | ||
| Q3 24 | $452.7M | $1.6B | ||
| Q2 24 | $289.4M | $1.6B | ||
| Q1 24 | $177.8M | $1.7B |
总资产HALORVMD
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.1B | $2.6B | ||
| Q3 24 | $2.1B | $1.8B | ||
| Q2 24 | $2.0B | $1.8B | ||
| Q1 24 | $1.8B | $1.9B |
负债/权益比HALORVMD
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $219.0M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $217.6M | $-139.5M |
| 自由现金流率自由现金流/营收 | 48.2% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $644.6M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流HALORVMD
| Q4 25 | $219.0M | — | ||
| Q3 25 | $178.6M | — | ||
| Q2 25 | $99.7M | — | ||
| Q1 25 | $154.2M | — | ||
| Q4 24 | $178.5M | $-138.3M | ||
| Q3 24 | $115.4M | $-130.4M | ||
| Q2 24 | $55.8M | $-128.2M | ||
| Q1 24 | $129.4M | $-160.6M |
自由现金流HALORVMD
| Q4 25 | $217.6M | — | ||
| Q3 25 | $175.6M | — | ||
| Q2 25 | $98.1M | — | ||
| Q1 25 | $153.3M | — | ||
| Q4 24 | $175.4M | $-139.5M | ||
| Q3 24 | $113.9M | $-133.9M | ||
| Q2 24 | $53.2M | $-130.6M | ||
| Q1 24 | $125.9M | $-163.7M |
自由现金流率HALORVMD
| Q4 25 | 48.2% | — | ||
| Q3 25 | 49.6% | — | ||
| Q2 25 | 30.1% | — | ||
| Q1 25 | 57.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 39.3% | — | ||
| Q2 24 | 23.0% | — | ||
| Q1 24 | 64.3% | — |
资本支出强度HALORVMD
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.8% | — |
现金转化率HALORVMD
| Q4 25 | — | — | ||
| Q3 25 | 1.02× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.31× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 1.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
RVMD
暂无分部数据
